Is it possible that some medications are not being approved because some people are non-responders versus the drug not being beneficial?

Yes, because a drug may be beneficial to a small proportion of people who are responders, present study designs may dilute results due to the non-responders. The authors of a recent study suggest the use of a study design called enriched enrolment with randomised withdrawal, EERW. In this study design, subjects are tried on a drug first, and only those who have a positive response are then randomised to study it further.

« Back
eOrthopod.com

All content provided by eOrthopod® is a registered trademark of Mosaic Medical Group, L.L.C.. Content is the sole property of Mosaic Medical Group, LLC and used herein by permission. Alteration of these documents in any way is a violation of the copyright.